Nanotechnology approaches to solving the problems of poorly water-soluble drugs

Drug Discovery World

Volumn 6, Issue 3, 2005, Pages 71-76

  Saffie Siebert, Roghieh ^a   Ogden, Jill ^a   Parry Billings, Mark ^a  

^a pSiMedica Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; GLIPIZIDE; INSULIN; MACROGOL; NEW DRUG; NIFEDIPINE; RAPAMYCIN; SILICON; SURFACTANT; VACCINE;

ARTICLE; BIOCOMPATIBILITY; BIOTECHNOLOGY; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG INDUSTRY; DRUG SOLUBILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; HYDROPHOBICITY; IDIOPATHIC DISEASE; IN VITRO STUDY; IN VIVO STUDY; NANOTECHNOLOGY; PROBLEM SOLVING; SIDE EFFECT;

EID: 22544469173     PISSN: 14694344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Tufts Center for the Study of Drug Development, Tufts University, Boston Mass USA: http://csdd.tufts.edu.
2. Dimond, PF. Using nanotechnologies in biotech and medicine. Gen. Eng. News 2005; 25: 21.
3. US Food and Drug Administration: Center for Drug Evaluation and Research. The Biopharmaceutics Classification System (BCS) Guidance. www.fda.gov/cder/OPS/BCS guidance.htm.
4. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. (August 2000). www.fda.gov/cder/guidance/index.htm.
5. Lindenberg, M, Kopp, S, Dressman, JB. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur. J. Pharm. Biopharm. 2004; 58: 265-278.
6. The Royal Society & The Royal Academy of Engineering. Nanoscience and nanotechnologies: opportunities and uncertainties. London (29 July 2004) www.royalsoc.ac.uk/policy.
7. US Food and Drug Administration (accessed May 18, 2005). www.fda.gov/nanotechnology/
8. Radtke, M, Souto, EB, Müller, RH. Nanostructured lipid carriers: a novel generation of solid lipid drug carriers. Pharm. Tech. Eur. 2005; 17(4): 45-50.
9. Hite, M, Turner, S, Federici, C. Oral delivery of poorly soluble drugs, part 2: formulation strategies for solid dosage forms and novel delivery systems for controlled release. Pharm. Manuf. Packing Sourcer 2003;Autumn.
10. Aston, R, Saffie-Siebert, R, Canham, L, Ogden, J. Nanotechnology applications for drug delivery. Pharm. Tech. Eur. 2005; 17(4): 21-28.
11. O'Neal, DP. Hirsch, LR, Halas, NJ, Payne, JD, West, JL. Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett. 2004; 209: 171-176.
12. Oberdorster, E. Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ. Health Perspect. 2004 Jul; 112(10): 1058-1062.
13. Oberdorster, G, Sharp, Z, Atudorei, V, Elder, A, Gelein, R, Kreyling, W, Cox, C. Translocation of inhaled ultrafine particles to the brain. Inhal. Toxicol. 2004 Jun; 16(6-7): 437-445.
14. Raloff, J. Nano hazards: exposure to minute particles harms lungs, circulatory system. Science News 2005; 167(12): 179-183. www.sciencenews.org/articles/20050319/fobl.asp
15. Luther, W (ed, NANOSAFE report) Industrial application of nanoparticles - chances and risks. Future Technologies series vol. 54, publ. VDI Technologiezentrum GmbH (Dusseldorf) 2004. (order free by e-mail: ztcpublikationendi.de)
16. BASF's position on nanotechnology: http://www.corporate.basf.com/en/innovationen/felder/nanotechnologie/ dialog.htm?id=VgPvC6pqObcp22P